淋巴细胞亚群作为芬戈莫德治疗复发型多发性硬化症患者治疗反应的生物标志物。
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
作者信息
Paolicelli D, Manni A, D'Onghia M, Direnzo V, Iaffaldano P, Zoccolella S, Di Lecce V, Tortorella C, Specchia G, Trojano M
机构信息
Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy.
出版信息
J Neuroimmunol. 2017 Feb 15;303:75-80. doi: 10.1016/j.jneuroim.2016.12.012. Epub 2016 Dec 21.
We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of Fingolimod (FTY) treated Relapsing MS (RMS) patients. Peripheral blood counts with LS, relapses and MRI scans were recorded in a cohort of 119 FTY patients, during one year of treatment. Simple and multivariate logistic regression models, were performed. ROC analysis identified cut-off values of LS predicting a higher risk of relapses and of Gd+ lesions. We demonstrated a FTY-induced re-modulation of the immune system, suggesting that LS in RMS FTY treated patients can predict the clinical response to the drug.
我们在芬戈莫德（FTY）治疗复发型多发性硬化症（RMS）患者的实际临床环境中，对淋巴细胞计数（LC）和淋巴细胞亚群（LS）进行了研究。在119例接受FTY治疗的患者队列中，记录了治疗一年期间外周血的LS计数、复发情况和MRI扫描结果。进行了单因素和多因素逻辑回归模型分析。ROC分析确定了LS预测复发和钆增强（Gd+）病灶高风险的临界值。我们证明了FTY可诱导免疫系统的重新调节，这表明接受FTY治疗的RMS患者的LS可预测对该药物的临床反应。
Zotero 插件